Company Overview of Maxygen, Inc.
Maxygen, Inc., a biopharmaceutical company, focuses on the discovery and development of protein pharmaceuticals for the treatment of disease and serious medical conditions in the United States. It focuses on developing MAXY-G34 product candidate, a granulocyte colony stimulating factor, for the treatment of chemotherapy-induced neutropenia and acute radiation syndrome. The company was founded in 1996 and is headquartered in San Mateo, California.
411 Borel Avenue
San Mateo, CA 94402
Founded in 1996
Key Executives for Maxygen, Inc.
Executive Chairman of The Board, Chief Executive Officer and Chief Financial Officer
Chief Patent Counsel and Vice President of Intellectual Property
Senior Vice President of Research and Development
Senior Vice President of Danish Operations and Senior Vice President of Global Project Management
General Counsel and Corporate Secretary
Compensation as of Fiscal Year 2014.
Maxygen, Inc. Key Developments
Maxygen, Inc. Announces Final Liquidating Distribution, Payable on About June 30, 2014
Jun 16 14
Maxygen, Inc. announced that, in accordance with the plan of dissolution approved by its shareholders on August 12, 2013, its Board of Directors has approved a second and final liquidating distribution in the amount of $0.093 per share of common stock. The final liquidating distribution will have a record date of August 29, 2013, which is the date on which the company filed its certificate of dissolution with the Secretary of State of Delaware and closed its stock transfer books. The company will make no further distributions beyond the final liquidating distribution. There is no requirement for stockholders to surrender shares in connection with the final liquidating distribution. Maxygen expects to pay this final liquidating distribution in cash on or about June 30, 2014.
Maxygen Files Form 15
Nov 1 13
Maxygen, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock under the Securities Exchange Act of 1934, as amended. The par value of the company's common stock was $0.0001 per share.
Maxygen Announces Filing Of Certificate of Dissolution; Delisting From NASDAQ
Aug 30 13
Maxygen, Inc. announced that it has filed a certificate of dissolution with the Secretary of State of the State of Delaware, which will become effective at 5:00 p.m. Eastern Time on August 29, 2013. The filing of the certificate was made pursuant to a plan of dissolution approved by shareholders at the company’s annual meeting held on August 12, 2013. Maxygen notified The NASDAQ Stock Market (NASDAQ) of the filing and NASDAQ has advised Maxygen that trading of the company’s common stock will be suspended after the regular market officially closes at 4:00 p.m. Eastern Time on August 29, 2013. NASDAQ also has advised Maxygen that it will file a Notification of Removal from Listing and/or Registration on Form 25 with the Securities and Exchange Commission (SEC) to delist the common stock from NASDAQ. Maxygen also intends to seek relief from the SEC to suspend certain of its reporting obligations under the Securities and Exchange Act of 1934, as amended. In connection with the effectiveness of the certificate of dissolution, Maxygen will also close its stock transfer books and discontinue recording transfers of its common stock, effective as of 5:00 p.m. Eastern Time on August 29, 2013. As a result, the common stock, and stock certificates evidencing the shares of common stock, will no longer be assignable or transferable on the company’s books, other than transfers by will, intestate succession or operation of law.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|